Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
LPI (LP Information)' newest research report, the “Oculopharyngeal Muscular Dystrophy (OPMD) Industry Forecast” looks at past sales and reviews total world Oculopharyngeal Muscular Dystrophy (OPMD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Oculopharyngeal Muscular Dystrophy (OPMD) sales for 2023 through 2029. With Oculopharyngeal Muscular Dystrophy (OPMD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oculopharyngeal Muscular Dystrophy (OPMD) industry.
This Insight Report provides a comprehensive analysis of the global Oculopharyngeal Muscular Dystrophy (OPMD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oculopharyngeal Muscular Dystrophy (OPMD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oculopharyngeal Muscular Dystrophy (OPMD) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oculopharyngeal Muscular Dystrophy (OPMD) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oculopharyngeal Muscular Dystrophy (OPMD).
The global Oculopharyngeal Muscular Dystrophy (OPMD) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Oculopharyngeal Muscular Dystrophy (OPMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oculopharyngeal Muscular Dystrophy (OPMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oculopharyngeal Muscular Dystrophy (OPMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oculopharyngeal Muscular Dystrophy (OPMD) players cover Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Oculopharyngeal Muscular Dystrophy (OPMD) market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Oculopharyngeal Muscular Dystrophy (OPMD) market?
What factors are driving Oculopharyngeal Muscular Dystrophy (OPMD) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oculopharyngeal Muscular Dystrophy (OPMD) market opportunities vary by end market size?
How does Oculopharyngeal Muscular Dystrophy (OPMD) break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
LPI (LP Information)' newest research report, the “Oculopharyngeal Muscular Dystrophy (OPMD) Industry Forecast” looks at past sales and reviews total world Oculopharyngeal Muscular Dystrophy (OPMD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Oculopharyngeal Muscular Dystrophy (OPMD) sales for 2023 through 2029. With Oculopharyngeal Muscular Dystrophy (OPMD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oculopharyngeal Muscular Dystrophy (OPMD) industry.
This Insight Report provides a comprehensive analysis of the global Oculopharyngeal Muscular Dystrophy (OPMD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oculopharyngeal Muscular Dystrophy (OPMD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oculopharyngeal Muscular Dystrophy (OPMD) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oculopharyngeal Muscular Dystrophy (OPMD) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oculopharyngeal Muscular Dystrophy (OPMD).
The global Oculopharyngeal Muscular Dystrophy (OPMD) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Oculopharyngeal Muscular Dystrophy (OPMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oculopharyngeal Muscular Dystrophy (OPMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oculopharyngeal Muscular Dystrophy (OPMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oculopharyngeal Muscular Dystrophy (OPMD) players cover Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Oculopharyngeal Muscular Dystrophy (OPMD) market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Tablets
- Capsules
- Injectable
- Other
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Benitec Biopharma Inc.
- Bioblast Pharma
- BioMarin
- PTC Therapeutics
- NS Pharma
- Nobelpharma Co., Ltd
- Santhera Pharmaceuticals
- Pfizer Inc.
- Marathon Pharmaceuticals
- Fibrogen
- Bristol-Myers Squibb
- Sarepta Therapeutics
- GSK
What is the 10-year outlook for the global Oculopharyngeal Muscular Dystrophy (OPMD) market?
What factors are driving Oculopharyngeal Muscular Dystrophy (OPMD) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oculopharyngeal Muscular Dystrophy (OPMD) market opportunities vary by end market size?
How does Oculopharyngeal Muscular Dystrophy (OPMD) break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oculopharyngeal Muscular Dystrophy (OPMD) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oculopharyngeal Muscular Dystrophy (OPMD) by Country/Region, 2018, 2022 & 2029
2.2 Oculopharyngeal Muscular Dystrophy (OPMD) Segment by Type
2.2.1 Tablets
2.2.2 Capsules
2.2.3 Injectable
2.2.4 Other
2.3 Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
2.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
2.3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue and Market Share by Type (2018-2023)
2.3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Type (2018-2023)
2.4 Oculopharyngeal Muscular Dystrophy (OPMD) Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
2.5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Market Share by Application (2018-2023)
2.5.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Application (2018-2023)
3 GLOBAL OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) BY COMPANY
3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Breakdown Data by Company
3.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Company (2018-2023)
3.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Company (2018-2023)
3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Company (2018-2023)
3.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Company (2018-2023)
3.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company (2018-2023)
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Company
3.4 Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Location Distribution
3.4.2 Players Oculopharyngeal Muscular Dystrophy (OPMD) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) BY GEOGRAPHIC REGION
4.1 World Historic Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Geographic Region (2018-2023)
4.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country/Region (2018-2023)
4.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.4 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.5 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.6 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
5 AMERICAS
5.1 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country
5.1.1 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023)
5.1.2 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023)
5.2 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
5.3 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region
6.1.1 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2018-2023)
6.1.2 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2018-2023)
6.2 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
6.3 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) by Country
7.1.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023)
7.1.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023)
7.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
7.3 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) by Country
8.1.1 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023)
8.2 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
8.3 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
10.3 Manufacturing Process Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
10.4 Industry Chain Structure of Oculopharyngeal Muscular Dystrophy (OPMD)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors
11.3 Oculopharyngeal Muscular Dystrophy (OPMD) Customer
12 WORLD FORECAST REVIEW FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) BY GEOGRAPHIC REGION
12.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Forecast by Region
12.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast by Region (2024-2029)
12.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast by Type
12.7 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Benitec Biopharma Inc.
13.1.1 Benitec Biopharma Inc. Company Information
13.1.2 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Benitec Biopharma Inc. Main Business Overview
13.1.5 Benitec Biopharma Inc. Latest Developments
13.2 Bioblast Pharma
13.2.1 Bioblast Pharma Company Information
13.2.2 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Bioblast Pharma Main Business Overview
13.2.5 Bioblast Pharma Latest Developments
13.3 BioMarin
13.3.1 BioMarin Company Information
13.3.2 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 BioMarin Main Business Overview
13.3.5 BioMarin Latest Developments
13.4 PTC Therapeutics
13.4.1 PTC Therapeutics Company Information
13.4.2 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 PTC Therapeutics Main Business Overview
13.4.5 PTC Therapeutics Latest Developments
13.5 NS Pharma
13.5.1 NS Pharma Company Information
13.5.2 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 NS Pharma Main Business Overview
13.5.5 NS Pharma Latest Developments
13.6 Nobelpharma Co., Ltd
13.6.1 Nobelpharma Co., Ltd Company Information
13.6.2 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Nobelpharma Co., Ltd Main Business Overview
13.6.5 Nobelpharma Co., Ltd Latest Developments
13.7 Santhera Pharmaceuticals
13.7.1 Santhera Pharmaceuticals Company Information
13.7.2 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Santhera Pharmaceuticals Main Business Overview
13.7.5 Santhera Pharmaceuticals Latest Developments
13.8 Pfizer Inc.
13.8.1 Pfizer Inc. Company Information
13.8.2 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Pfizer Inc. Main Business Overview
13.8.5 Pfizer Inc. Latest Developments
13.9 Marathon Pharmaceuticals
13.9.1 Marathon Pharmaceuticals Company Information
13.9.2 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Marathon Pharmaceuticals Main Business Overview
13.9.5 Marathon Pharmaceuticals Latest Developments
13.10 Fibrogen
13.10.1 Fibrogen Company Information
13.10.2 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Fibrogen Main Business Overview
13.10.5 Fibrogen Latest Developments
13.11 Bristol-Myers Squibb
13.11.1 Bristol-Myers Squibb Company Information
13.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Bristol-Myers Squibb Main Business Overview
13.11.5 Bristol-Myers Squibb Latest Developments
13.12 Sarepta Therapeutics
13.12.1 Sarepta Therapeutics Company Information
13.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sarepta Therapeutics Main Business Overview
13.12.5 Sarepta Therapeutics Latest Developments
13.13 GSK
13.13.1 GSK Company Information
13.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 GSK Main Business Overview
13.13.5 GSK Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oculopharyngeal Muscular Dystrophy (OPMD) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oculopharyngeal Muscular Dystrophy (OPMD) by Country/Region, 2018, 2022 & 2029
2.2 Oculopharyngeal Muscular Dystrophy (OPMD) Segment by Type
2.2.1 Tablets
2.2.2 Capsules
2.2.3 Injectable
2.2.4 Other
2.3 Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
2.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
2.3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue and Market Share by Type (2018-2023)
2.3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Type (2018-2023)
2.4 Oculopharyngeal Muscular Dystrophy (OPMD) Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
2.5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Market Share by Application (2018-2023)
2.5.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Application (2018-2023)
3 GLOBAL OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) BY COMPANY
3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Breakdown Data by Company
3.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Company (2018-2023)
3.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Company (2018-2023)
3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Company (2018-2023)
3.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Company (2018-2023)
3.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company (2018-2023)
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Company
3.4 Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Location Distribution
3.4.2 Players Oculopharyngeal Muscular Dystrophy (OPMD) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) BY GEOGRAPHIC REGION
4.1 World Historic Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Geographic Region (2018-2023)
4.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country/Region (2018-2023)
4.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.4 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.5 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.6 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
5 AMERICAS
5.1 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country
5.1.1 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023)
5.1.2 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023)
5.2 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
5.3 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region
6.1.1 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2018-2023)
6.1.2 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2018-2023)
6.2 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
6.3 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) by Country
7.1.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023)
7.1.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023)
7.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
7.3 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) by Country
8.1.1 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023)
8.2 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type
8.3 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
10.3 Manufacturing Process Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
10.4 Industry Chain Structure of Oculopharyngeal Muscular Dystrophy (OPMD)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors
11.3 Oculopharyngeal Muscular Dystrophy (OPMD) Customer
12 WORLD FORECAST REVIEW FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) BY GEOGRAPHIC REGION
12.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Forecast by Region
12.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast by Region (2024-2029)
12.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast by Type
12.7 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Benitec Biopharma Inc.
13.1.1 Benitec Biopharma Inc. Company Information
13.1.2 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Benitec Biopharma Inc. Main Business Overview
13.1.5 Benitec Biopharma Inc. Latest Developments
13.2 Bioblast Pharma
13.2.1 Bioblast Pharma Company Information
13.2.2 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Bioblast Pharma Main Business Overview
13.2.5 Bioblast Pharma Latest Developments
13.3 BioMarin
13.3.1 BioMarin Company Information
13.3.2 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 BioMarin Main Business Overview
13.3.5 BioMarin Latest Developments
13.4 PTC Therapeutics
13.4.1 PTC Therapeutics Company Information
13.4.2 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 PTC Therapeutics Main Business Overview
13.4.5 PTC Therapeutics Latest Developments
13.5 NS Pharma
13.5.1 NS Pharma Company Information
13.5.2 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 NS Pharma Main Business Overview
13.5.5 NS Pharma Latest Developments
13.6 Nobelpharma Co., Ltd
13.6.1 Nobelpharma Co., Ltd Company Information
13.6.2 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Nobelpharma Co., Ltd Main Business Overview
13.6.5 Nobelpharma Co., Ltd Latest Developments
13.7 Santhera Pharmaceuticals
13.7.1 Santhera Pharmaceuticals Company Information
13.7.2 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Santhera Pharmaceuticals Main Business Overview
13.7.5 Santhera Pharmaceuticals Latest Developments
13.8 Pfizer Inc.
13.8.1 Pfizer Inc. Company Information
13.8.2 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Pfizer Inc. Main Business Overview
13.8.5 Pfizer Inc. Latest Developments
13.9 Marathon Pharmaceuticals
13.9.1 Marathon Pharmaceuticals Company Information
13.9.2 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Marathon Pharmaceuticals Main Business Overview
13.9.5 Marathon Pharmaceuticals Latest Developments
13.10 Fibrogen
13.10.1 Fibrogen Company Information
13.10.2 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Fibrogen Main Business Overview
13.10.5 Fibrogen Latest Developments
13.11 Bristol-Myers Squibb
13.11.1 Bristol-Myers Squibb Company Information
13.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Bristol-Myers Squibb Main Business Overview
13.11.5 Bristol-Myers Squibb Latest Developments
13.12 Sarepta Therapeutics
13.12.1 Sarepta Therapeutics Company Information
13.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sarepta Therapeutics Main Business Overview
13.12.5 Sarepta Therapeutics Latest Developments
13.13 GSK
13.13.1 GSK Company Information
13.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
13.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 GSK Main Business Overview
13.13.5 GSK Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Tablets
Table 4. Major Players of Capsules
Table 5. Major Players of Injectable
Table 6. Major Players of Other
Table 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 8. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Table 9. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Type (2018-2023) & ($ million)
Table 10. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Type (2018-2023)
Table 11. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Table 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Application (2018-2023)
Table 15. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Application (2018-2023)
Table 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Company (2018-2023) & (K Units)
Table 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Company (2018-2023)
Table 19. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company (2018-2023)
Table 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Producing Area Distribution and Sales Area
Table 23. Players Oculopharyngeal Muscular Dystrophy (OPMD) Products Offered
Table 24. Oculopharyngeal Muscular Dystrophy (OPMD) Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Geographic Region (2018-2023)
Table 29. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country/Region (2018-2023)
Table 33. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 36. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2023)
Table 37. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2023)
Table 39. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 40. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 41. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2018-2023) & (K Units)
Table 42. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2018-2023)
Table 43. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2018-2023)
Table 45. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 46. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 47. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 48. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2023)
Table 49. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2023)
Table 51. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 52. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 60. Key Market Challenges & Risks of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 61. Key Industry Trends of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 62. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors List
Table 65. Oculopharyngeal Muscular Dystrophy (OPMD) Customer List
Table 66. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Benitec Biopharma Inc. Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 81. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 82. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Benitec Biopharma Inc. Main Business
Table 84. Benitec Biopharma Inc. Latest Developments
Table 85. Bioblast Pharma Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 86. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 87. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Bioblast Pharma Main Business
Table 89. Bioblast Pharma Latest Developments
Table 90. BioMarin Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 91. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 92. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. BioMarin Main Business
Table 94. BioMarin Latest Developments
Table 95. PTC Therapeutics Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 96. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 97. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. PTC Therapeutics Main Business
Table 99. PTC Therapeutics Latest Developments
Table 100. NS Pharma Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 101. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 102. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. NS Pharma Main Business
Table 104. NS Pharma Latest Developments
Table 105. Nobelpharma Co., Ltd Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 106. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 107. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Nobelpharma Co., Ltd Main Business
Table 109. Nobelpharma Co., Ltd Latest Developments
Table 110. Santhera Pharmaceuticals Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 111. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 112. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Santhera Pharmaceuticals Main Business
Table 114. Santhera Pharmaceuticals Latest Developments
Table 115. Pfizer Inc. Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 116. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 117. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Pfizer Inc. Main Business
Table 119. Pfizer Inc. Latest Developments
Table 120. Marathon Pharmaceuticals Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 121. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 122. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Marathon Pharmaceuticals Main Business
Table 124. Marathon Pharmaceuticals Latest Developments
Table 125. Fibrogen Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 126. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 127. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Fibrogen Main Business
Table 129. Fibrogen Latest Developments
Table 130. Bristol-Myers Squibb Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 131. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 132. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Bristol-Myers Squibb Main Business
Table 134. Bristol-Myers Squibb Latest Developments
Table 135. Sarepta Therapeutics Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 136. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 137. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Sarepta Therapeutics Main Business
Table 139. Sarepta Therapeutics Latest Developments
Table 140. GSK Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 141. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 142. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. GSK Main Business
Table 144. GSK Latest Developments
Table 1. Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Tablets
Table 4. Major Players of Capsules
Table 5. Major Players of Injectable
Table 6. Major Players of Other
Table 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 8. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Table 9. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Type (2018-2023) & ($ million)
Table 10. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Type (2018-2023)
Table 11. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Table 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Application (2018-2023)
Table 15. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Application (2018-2023)
Table 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Company (2018-2023) & (K Units)
Table 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Company (2018-2023)
Table 19. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company (2018-2023)
Table 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Producing Area Distribution and Sales Area
Table 23. Players Oculopharyngeal Muscular Dystrophy (OPMD) Products Offered
Table 24. Oculopharyngeal Muscular Dystrophy (OPMD) Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Geographic Region (2018-2023)
Table 29. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country/Region (2018-2023)
Table 33. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 36. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2023)
Table 37. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2023)
Table 39. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 40. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 41. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2018-2023) & (K Units)
Table 42. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2018-2023)
Table 43. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2018-2023)
Table 45. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 46. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 47. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 48. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2023)
Table 49. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2023)
Table 51. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 52. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 60. Key Market Challenges & Risks of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 61. Key Industry Trends of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 62. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors List
Table 65. Oculopharyngeal Muscular Dystrophy (OPMD) Customer List
Table 66. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Benitec Biopharma Inc. Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 81. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 82. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Benitec Biopharma Inc. Main Business
Table 84. Benitec Biopharma Inc. Latest Developments
Table 85. Bioblast Pharma Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 86. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 87. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Bioblast Pharma Main Business
Table 89. Bioblast Pharma Latest Developments
Table 90. BioMarin Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 91. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 92. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. BioMarin Main Business
Table 94. BioMarin Latest Developments
Table 95. PTC Therapeutics Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 96. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 97. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. PTC Therapeutics Main Business
Table 99. PTC Therapeutics Latest Developments
Table 100. NS Pharma Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 101. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 102. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. NS Pharma Main Business
Table 104. NS Pharma Latest Developments
Table 105. Nobelpharma Co., Ltd Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 106. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 107. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Nobelpharma Co., Ltd Main Business
Table 109. Nobelpharma Co., Ltd Latest Developments
Table 110. Santhera Pharmaceuticals Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 111. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 112. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Santhera Pharmaceuticals Main Business
Table 114. Santhera Pharmaceuticals Latest Developments
Table 115. Pfizer Inc. Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 116. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 117. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Pfizer Inc. Main Business
Table 119. Pfizer Inc. Latest Developments
Table 120. Marathon Pharmaceuticals Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 121. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 122. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Marathon Pharmaceuticals Main Business
Table 124. Marathon Pharmaceuticals Latest Developments
Table 125. Fibrogen Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 126. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 127. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Fibrogen Main Business
Table 129. Fibrogen Latest Developments
Table 130. Bristol-Myers Squibb Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 131. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 132. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Bristol-Myers Squibb Main Business
Table 134. Bristol-Myers Squibb Latest Developments
Table 135. Sarepta Therapeutics Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 136. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 137. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Sarepta Therapeutics Main Business
Table 139. Sarepta Therapeutics Latest Developments
Table 140. GSK Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 141. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolios and Specifications
Table 142. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. GSK Main Business
Table 144. GSK Latest Developments
LIST OF FIGURES
Figure 1. Picture of Oculopharyngeal Muscular Dystrophy (OPMD)
Figure 2. Oculopharyngeal Muscular Dystrophy (OPMD) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Tablets
Figure 10. Product Picture of Capsules
Figure 11. Product Picture of Injectable
Figure 12. Product Picture of Other
Figure 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type in 2022
Figure 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Type (2018-2023)
Figure 15. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Hospital Pharmacies
Figure 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 17. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Retail Pharmacies
Figure 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 19. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Online Pharmacies
Figure 20. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Online Pharmacies (2018-2023) & (K Units)
Figure 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2022)
Figure 22. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Application in 2022
Figure 23. Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market by Company in 2022 (K Units)
Figure 24. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Company in 2022
Figure 25. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company in 2022
Figure 27. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2023 (K Units)
Figure 30. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2023 ($ Millions)
Figure 31. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2023 (K Units)
Figure 32. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2023 ($ Millions)
Figure 33. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2023 (K Units)
Figure 34. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2023 ($ Millions)
Figure 37. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country in 2022
Figure 38. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country in 2022
Figure 39. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Figure 40. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Figure 41. United States Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region in 2022
Figure 46. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Regions in 2022
Figure 47. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Figure 48. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Figure 49. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country in 2022
Figure 57. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country in 2022
Figure 58. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Figure 59. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Figure 60. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Figure 69. Egypt Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Oculopharyngeal Muscular Dystrophy (OPMD) in 2022
Figure 75. Manufacturing Process Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
Figure 76. Industry Chain Structure of Oculopharyngeal Muscular Dystrophy (OPMD)
Figure 77. Channels of Distribution
Figure 78. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Forecast by Region (2024-2029)
Figure 79. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Oculopharyngeal Muscular Dystrophy (OPMD)
Figure 2. Oculopharyngeal Muscular Dystrophy (OPMD) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Tablets
Figure 10. Product Picture of Capsules
Figure 11. Product Picture of Injectable
Figure 12. Product Picture of Other
Figure 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type in 2022
Figure 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Type (2018-2023)
Figure 15. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Hospital Pharmacies
Figure 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 17. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Retail Pharmacies
Figure 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 19. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Online Pharmacies
Figure 20. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Online Pharmacies (2018-2023) & (K Units)
Figure 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2022)
Figure 22. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Application in 2022
Figure 23. Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market by Company in 2022 (K Units)
Figure 24. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Company in 2022
Figure 25. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company in 2022
Figure 27. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2023 (K Units)
Figure 30. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2023 ($ Millions)
Figure 31. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2023 (K Units)
Figure 32. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2023 ($ Millions)
Figure 33. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2023 (K Units)
Figure 34. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2023 ($ Millions)
Figure 37. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country in 2022
Figure 38. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country in 2022
Figure 39. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Figure 40. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Figure 41. United States Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region in 2022
Figure 46. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Regions in 2022
Figure 47. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Figure 48. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Figure 49. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country in 2022
Figure 57. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country in 2022
Figure 58. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Figure 59. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Figure 60. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Figure 69. Egypt Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Oculopharyngeal Muscular Dystrophy (OPMD) in 2022
Figure 75. Manufacturing Process Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
Figure 76. Industry Chain Structure of Oculopharyngeal Muscular Dystrophy (OPMD)
Figure 77. Channels of Distribution
Figure 78. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Forecast by Region (2024-2029)
Figure 79. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast by Application (2024-2029)
